A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors

Eli Lilly and Company0 sites555 target enrollmentJanuary 20, 2011

Overview

No summary available.

Registry

who.int

Start Date

January 20, 2011

End Date

TBD

Last Updated

11 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Patients will be male and female aged \=18 years of age with a diagnosis of moderately to severely active adult onset RA
•Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years
•At least 8 tender and swollen joints
•An abnormally high C\-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR)
•Positive for Rheumatoid Factor (RF) or Anti\-cyclic citrullinated peptide (CCP) antibody
•Previously treated with biologic TNF\-a inhibitor therapy (infliximab, certolizumab, golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy or intolerance
•Regular use of at least one conventional disease\-modifying anti\-rheumatic drug (DMARD), with a stable dose for at least 8 weeks prior to study start
•Woman must not be pregnant, breastfeeding, or become pregnant during the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:

•Use of unstable doses of non\-steroidal inflammatory drugs (NSAIDS) in the past 6 weeks
•Steroid injection or intravenous (IV) infusion in the last 6 weeks
•Use of more than 10 mg/day of oral steroids in the last 6 weeks
•History of a serious reaction to other biological DMARDs
•Use of an oral calcineurin inhibitor (e.g., cyclosporin or tacrolimus) in the last 8 weeks
•Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study
•Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA
•Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years
•Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal\-spray flu vaccines)
•Hepatitis or human immunodeficiency virus (HIV)